Loading…

PATH-27. MOLECULAR, IMAGING, AND SURVIVAL MANIFESTATIONS IN MOLECULAR GLIOBLASTOMAS: INSIGHTS FROM A MULTI-NATIONAL STUDY

Abstract Apart from the traditional definition of IDH-wildtype GBM based on histological characteristics, IDH-wildtype diffuse gliomas previously assigned to histological grade 2 or 3 are now defined as IDH-wildtype GBM in the presence of qualifying molecular markers (TERTp mutation, EGFR amplificat...

Full description

Saved in:
Bibliographic Details
Published in:Neuro-oncology (Charlottesville, Va.) Va.), 2024-11, Vol.26 (Supplement_8), p.viii184-viii184
Main Authors: Park, Yae Won, Youssef, Gilbert, Freeman, Nicolas, Teske, Nico, Karschnia, Philipp, Foltyn-Dumitru, Martha, Banan, Rouzbeh, Lee, Matthew, Singh, Kanwar, Park, Ji Eun, Choi, Kyu Sung, Wongsawaeng, Doonyaporn, Chang, Jong Hee, Kim, Se Hoon, Lee, Seung-Koo, Wen, Patrick Y, Barajas Jr, Ramon Francisco, Choi, Seung Hong, Kim, Ho Sung, Jain, Rajan, Sahm, Felix, Wick, Wolfgang, Bendszus, Martin, Vollmuth, Philipp, Thon, Niklas, Huang, Raymond, Ahn, Sung Soo
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page viii184
container_issue Supplement_8
container_start_page viii184
container_title Neuro-oncology (Charlottesville, Va.)
container_volume 26
creator Park, Yae Won
Youssef, Gilbert
Freeman, Nicolas
Teske, Nico
Karschnia, Philipp
Foltyn-Dumitru, Martha
Banan, Rouzbeh
Lee, Matthew
Singh, Kanwar
Park, Ji Eun
Choi, Kyu Sung
Wongsawaeng, Doonyaporn
Chang, Jong Hee
Kim, Se Hoon
Lee, Seung-Koo
Wen, Patrick Y
Barajas Jr, Ramon Francisco
Choi, Seung Hong
Kim, Ho Sung
Jain, Rajan
Sahm, Felix
Wick, Wolfgang
Bendszus, Martin
Vollmuth, Philipp
Thon, Niklas
Huang, Raymond
Ahn, Sung Soo
description Abstract Apart from the traditional definition of IDH-wildtype GBM based on histological characteristics, IDH-wildtype diffuse gliomas previously assigned to histological grade 2 or 3 are now defined as IDH-wildtype GBM in the presence of qualifying molecular markers (TERTp mutation, EGFR amplification, or chromosome +7/-10) (“molecular GBM”) in the 2021 WHO classification. However, the clinical significance of molecular GBM is unrevealed. This collaboration aims to comprehensively evaluate the clinical, molecular, imaging characteristics, and prognosis of molecular GBMs in a multi-national dataset and stratify survival. Retrospective chart and imaging review was performed in 258 molecular GBM patients from eight centers across three continents. Clinical, molecular, imaging, and survival characteristics were analyzed. The median age of molecular GBM patients was 58 years (range: 23-83) with 139 males, with TERTp mutation (83 of 214 [38.8%]), EGFR amplification (160 of 204 [78.4%]), and chromosome +7/-10 (82 of 143 patients [57.3%]). The majority of tumors were located at the frontal and temporal lobes (48.4%) and exhibited non-contrast-enhancing (CE) tumors (73.7%). Gliomatosis cerebri pattern was shown with 27 patients (12.4%). The median OS was 28.1 months (95% confidence interval 22.1-34.1). There was significantly shorter survival in patients with high Ki-67 index (> 20) compared to those with low Ki-67 index (median OS 19.3 vs. 31.5 months, log-rank test P = 0.002), while no survival differences were found according to histological grade or molecular diagnostics. Survival was significantly shorter in patients with infiltrative imaging appearance compared to those without (median OS 24.7 vs 41.0 months, log-rank test P = 0.014). In conclusion, survival within molecular GBM patients may be heterogeneous and associated with Ki-67 index and infiltrative imaging appearance.
doi_str_mv 10.1093/neuonc/noae165.0726
format article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_neuonc_noae165_0726</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/neuonc/noae165.0726</oup_id><sourcerecordid>10.1093/neuonc/noae165.0726</sourcerecordid><originalsourceid>FETCH-LOGICAL-c836-7b1e7b90dd758b9dbdcc374c9cfbe22b749f5118acb2440f0cdcb6283c5a3dde3</originalsourceid><addsrcrecordid>eNqNkMlqwzAAREVpoWnaL-hFHxA7WizL7k3N4ghku0RyoCdjyTa0tHGwySF_nxV67WkGhjeHB8ArRj5GMZ1um323ddNtVzU4ZD7iJLwDI8wI9VgUhveXTryIYf4InobhGyGCWYhH4PAhzMoj3IdprhazQon1BMpUJDJLJlBkc6iL9UZuhIKpyORyoY0wMs80lNkfAhMl83cltMlTod9Om5bJymi4XOcpFDAtlJFediFPT9oU889n8NBWP0PzcssxMMuFma08lSdyJpTnIhp63OKG2xjVNWeRjWtbO0d54GLX2oYQy4O4ZRhHlbMkCFCLXO1sSCLqWEXruqFjQK-3ru-GoW_actd__Vb9ocSoPMsrr_LKm7zyLO9E-Veq2-_-BRwBkY9srg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>PATH-27. MOLECULAR, IMAGING, AND SURVIVAL MANIFESTATIONS IN MOLECULAR GLIOBLASTOMAS: INSIGHTS FROM A MULTI-NATIONAL STUDY</title><source>Oxford Journals Online</source><creator>Park, Yae Won ; Youssef, Gilbert ; Freeman, Nicolas ; Teske, Nico ; Karschnia, Philipp ; Foltyn-Dumitru, Martha ; Banan, Rouzbeh ; Lee, Matthew ; Singh, Kanwar ; Park, Ji Eun ; Choi, Kyu Sung ; Wongsawaeng, Doonyaporn ; Chang, Jong Hee ; Kim, Se Hoon ; Lee, Seung-Koo ; Wen, Patrick Y ; Barajas Jr, Ramon Francisco ; Choi, Seung Hong ; Kim, Ho Sung ; Jain, Rajan ; Sahm, Felix ; Wick, Wolfgang ; Bendszus, Martin ; Vollmuth, Philipp ; Thon, Niklas ; Huang, Raymond ; Ahn, Sung Soo</creator><creatorcontrib>Park, Yae Won ; Youssef, Gilbert ; Freeman, Nicolas ; Teske, Nico ; Karschnia, Philipp ; Foltyn-Dumitru, Martha ; Banan, Rouzbeh ; Lee, Matthew ; Singh, Kanwar ; Park, Ji Eun ; Choi, Kyu Sung ; Wongsawaeng, Doonyaporn ; Chang, Jong Hee ; Kim, Se Hoon ; Lee, Seung-Koo ; Wen, Patrick Y ; Barajas Jr, Ramon Francisco ; Choi, Seung Hong ; Kim, Ho Sung ; Jain, Rajan ; Sahm, Felix ; Wick, Wolfgang ; Bendszus, Martin ; Vollmuth, Philipp ; Thon, Niklas ; Huang, Raymond ; Ahn, Sung Soo</creatorcontrib><description>Abstract Apart from the traditional definition of IDH-wildtype GBM based on histological characteristics, IDH-wildtype diffuse gliomas previously assigned to histological grade 2 or 3 are now defined as IDH-wildtype GBM in the presence of qualifying molecular markers (TERTp mutation, EGFR amplification, or chromosome +7/-10) (“molecular GBM”) in the 2021 WHO classification. However, the clinical significance of molecular GBM is unrevealed. This collaboration aims to comprehensively evaluate the clinical, molecular, imaging characteristics, and prognosis of molecular GBMs in a multi-national dataset and stratify survival. Retrospective chart and imaging review was performed in 258 molecular GBM patients from eight centers across three continents. Clinical, molecular, imaging, and survival characteristics were analyzed. The median age of molecular GBM patients was 58 years (range: 23-83) with 139 males, with TERTp mutation (83 of 214 [38.8%]), EGFR amplification (160 of 204 [78.4%]), and chromosome +7/-10 (82 of 143 patients [57.3%]). The majority of tumors were located at the frontal and temporal lobes (48.4%) and exhibited non-contrast-enhancing (CE) tumors (73.7%). Gliomatosis cerebri pattern was shown with 27 patients (12.4%). The median OS was 28.1 months (95% confidence interval 22.1-34.1). There was significantly shorter survival in patients with high Ki-67 index (&gt; 20) compared to those with low Ki-67 index (median OS 19.3 vs. 31.5 months, log-rank test P = 0.002), while no survival differences were found according to histological grade or molecular diagnostics. Survival was significantly shorter in patients with infiltrative imaging appearance compared to those without (median OS 24.7 vs 41.0 months, log-rank test P = 0.014). In conclusion, survival within molecular GBM patients may be heterogeneous and associated with Ki-67 index and infiltrative imaging appearance.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/noae165.0726</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>Neuro-oncology (Charlottesville, Va.), 2024-11, Vol.26 (Supplement_8), p.viii184-viii184</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Park, Yae Won</creatorcontrib><creatorcontrib>Youssef, Gilbert</creatorcontrib><creatorcontrib>Freeman, Nicolas</creatorcontrib><creatorcontrib>Teske, Nico</creatorcontrib><creatorcontrib>Karschnia, Philipp</creatorcontrib><creatorcontrib>Foltyn-Dumitru, Martha</creatorcontrib><creatorcontrib>Banan, Rouzbeh</creatorcontrib><creatorcontrib>Lee, Matthew</creatorcontrib><creatorcontrib>Singh, Kanwar</creatorcontrib><creatorcontrib>Park, Ji Eun</creatorcontrib><creatorcontrib>Choi, Kyu Sung</creatorcontrib><creatorcontrib>Wongsawaeng, Doonyaporn</creatorcontrib><creatorcontrib>Chang, Jong Hee</creatorcontrib><creatorcontrib>Kim, Se Hoon</creatorcontrib><creatorcontrib>Lee, Seung-Koo</creatorcontrib><creatorcontrib>Wen, Patrick Y</creatorcontrib><creatorcontrib>Barajas Jr, Ramon Francisco</creatorcontrib><creatorcontrib>Choi, Seung Hong</creatorcontrib><creatorcontrib>Kim, Ho Sung</creatorcontrib><creatorcontrib>Jain, Rajan</creatorcontrib><creatorcontrib>Sahm, Felix</creatorcontrib><creatorcontrib>Wick, Wolfgang</creatorcontrib><creatorcontrib>Bendszus, Martin</creatorcontrib><creatorcontrib>Vollmuth, Philipp</creatorcontrib><creatorcontrib>Thon, Niklas</creatorcontrib><creatorcontrib>Huang, Raymond</creatorcontrib><creatorcontrib>Ahn, Sung Soo</creatorcontrib><title>PATH-27. MOLECULAR, IMAGING, AND SURVIVAL MANIFESTATIONS IN MOLECULAR GLIOBLASTOMAS: INSIGHTS FROM A MULTI-NATIONAL STUDY</title><title>Neuro-oncology (Charlottesville, Va.)</title><description>Abstract Apart from the traditional definition of IDH-wildtype GBM based on histological characteristics, IDH-wildtype diffuse gliomas previously assigned to histological grade 2 or 3 are now defined as IDH-wildtype GBM in the presence of qualifying molecular markers (TERTp mutation, EGFR amplification, or chromosome +7/-10) (“molecular GBM”) in the 2021 WHO classification. However, the clinical significance of molecular GBM is unrevealed. This collaboration aims to comprehensively evaluate the clinical, molecular, imaging characteristics, and prognosis of molecular GBMs in a multi-national dataset and stratify survival. Retrospective chart and imaging review was performed in 258 molecular GBM patients from eight centers across three continents. Clinical, molecular, imaging, and survival characteristics were analyzed. The median age of molecular GBM patients was 58 years (range: 23-83) with 139 males, with TERTp mutation (83 of 214 [38.8%]), EGFR amplification (160 of 204 [78.4%]), and chromosome +7/-10 (82 of 143 patients [57.3%]). The majority of tumors were located at the frontal and temporal lobes (48.4%) and exhibited non-contrast-enhancing (CE) tumors (73.7%). Gliomatosis cerebri pattern was shown with 27 patients (12.4%). The median OS was 28.1 months (95% confidence interval 22.1-34.1). There was significantly shorter survival in patients with high Ki-67 index (&gt; 20) compared to those with low Ki-67 index (median OS 19.3 vs. 31.5 months, log-rank test P = 0.002), while no survival differences were found according to histological grade or molecular diagnostics. Survival was significantly shorter in patients with infiltrative imaging appearance compared to those without (median OS 24.7 vs 41.0 months, log-rank test P = 0.014). In conclusion, survival within molecular GBM patients may be heterogeneous and associated with Ki-67 index and infiltrative imaging appearance.</description><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqNkMlqwzAAREVpoWnaL-hFHxA7WizL7k3N4ghku0RyoCdjyTa0tHGwySF_nxV67WkGhjeHB8ArRj5GMZ1um323ddNtVzU4ZD7iJLwDI8wI9VgUhveXTryIYf4InobhGyGCWYhH4PAhzMoj3IdprhazQon1BMpUJDJLJlBkc6iL9UZuhIKpyORyoY0wMs80lNkfAhMl83cltMlTod9Om5bJymi4XOcpFDAtlJFediFPT9oU889n8NBWP0PzcssxMMuFma08lSdyJpTnIhp63OKG2xjVNWeRjWtbO0d54GLX2oYQy4O4ZRhHlbMkCFCLXO1sSCLqWEXruqFjQK-3ru-GoW_actd__Vb9ocSoPMsrr_LKm7zyLO9E-Veq2-_-BRwBkY9srg</recordid><startdate>20241111</startdate><enddate>20241111</enddate><creator>Park, Yae Won</creator><creator>Youssef, Gilbert</creator><creator>Freeman, Nicolas</creator><creator>Teske, Nico</creator><creator>Karschnia, Philipp</creator><creator>Foltyn-Dumitru, Martha</creator><creator>Banan, Rouzbeh</creator><creator>Lee, Matthew</creator><creator>Singh, Kanwar</creator><creator>Park, Ji Eun</creator><creator>Choi, Kyu Sung</creator><creator>Wongsawaeng, Doonyaporn</creator><creator>Chang, Jong Hee</creator><creator>Kim, Se Hoon</creator><creator>Lee, Seung-Koo</creator><creator>Wen, Patrick Y</creator><creator>Barajas Jr, Ramon Francisco</creator><creator>Choi, Seung Hong</creator><creator>Kim, Ho Sung</creator><creator>Jain, Rajan</creator><creator>Sahm, Felix</creator><creator>Wick, Wolfgang</creator><creator>Bendszus, Martin</creator><creator>Vollmuth, Philipp</creator><creator>Thon, Niklas</creator><creator>Huang, Raymond</creator><creator>Ahn, Sung Soo</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20241111</creationdate><title>PATH-27. MOLECULAR, IMAGING, AND SURVIVAL MANIFESTATIONS IN MOLECULAR GLIOBLASTOMAS: INSIGHTS FROM A MULTI-NATIONAL STUDY</title><author>Park, Yae Won ; Youssef, Gilbert ; Freeman, Nicolas ; Teske, Nico ; Karschnia, Philipp ; Foltyn-Dumitru, Martha ; Banan, Rouzbeh ; Lee, Matthew ; Singh, Kanwar ; Park, Ji Eun ; Choi, Kyu Sung ; Wongsawaeng, Doonyaporn ; Chang, Jong Hee ; Kim, Se Hoon ; Lee, Seung-Koo ; Wen, Patrick Y ; Barajas Jr, Ramon Francisco ; Choi, Seung Hong ; Kim, Ho Sung ; Jain, Rajan ; Sahm, Felix ; Wick, Wolfgang ; Bendszus, Martin ; Vollmuth, Philipp ; Thon, Niklas ; Huang, Raymond ; Ahn, Sung Soo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c836-7b1e7b90dd758b9dbdcc374c9cfbe22b749f5118acb2440f0cdcb6283c5a3dde3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Yae Won</creatorcontrib><creatorcontrib>Youssef, Gilbert</creatorcontrib><creatorcontrib>Freeman, Nicolas</creatorcontrib><creatorcontrib>Teske, Nico</creatorcontrib><creatorcontrib>Karschnia, Philipp</creatorcontrib><creatorcontrib>Foltyn-Dumitru, Martha</creatorcontrib><creatorcontrib>Banan, Rouzbeh</creatorcontrib><creatorcontrib>Lee, Matthew</creatorcontrib><creatorcontrib>Singh, Kanwar</creatorcontrib><creatorcontrib>Park, Ji Eun</creatorcontrib><creatorcontrib>Choi, Kyu Sung</creatorcontrib><creatorcontrib>Wongsawaeng, Doonyaporn</creatorcontrib><creatorcontrib>Chang, Jong Hee</creatorcontrib><creatorcontrib>Kim, Se Hoon</creatorcontrib><creatorcontrib>Lee, Seung-Koo</creatorcontrib><creatorcontrib>Wen, Patrick Y</creatorcontrib><creatorcontrib>Barajas Jr, Ramon Francisco</creatorcontrib><creatorcontrib>Choi, Seung Hong</creatorcontrib><creatorcontrib>Kim, Ho Sung</creatorcontrib><creatorcontrib>Jain, Rajan</creatorcontrib><creatorcontrib>Sahm, Felix</creatorcontrib><creatorcontrib>Wick, Wolfgang</creatorcontrib><creatorcontrib>Bendszus, Martin</creatorcontrib><creatorcontrib>Vollmuth, Philipp</creatorcontrib><creatorcontrib>Thon, Niklas</creatorcontrib><creatorcontrib>Huang, Raymond</creatorcontrib><creatorcontrib>Ahn, Sung Soo</creatorcontrib><collection>CrossRef</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Yae Won</au><au>Youssef, Gilbert</au><au>Freeman, Nicolas</au><au>Teske, Nico</au><au>Karschnia, Philipp</au><au>Foltyn-Dumitru, Martha</au><au>Banan, Rouzbeh</au><au>Lee, Matthew</au><au>Singh, Kanwar</au><au>Park, Ji Eun</au><au>Choi, Kyu Sung</au><au>Wongsawaeng, Doonyaporn</au><au>Chang, Jong Hee</au><au>Kim, Se Hoon</au><au>Lee, Seung-Koo</au><au>Wen, Patrick Y</au><au>Barajas Jr, Ramon Francisco</au><au>Choi, Seung Hong</au><au>Kim, Ho Sung</au><au>Jain, Rajan</au><au>Sahm, Felix</au><au>Wick, Wolfgang</au><au>Bendszus, Martin</au><au>Vollmuth, Philipp</au><au>Thon, Niklas</au><au>Huang, Raymond</au><au>Ahn, Sung Soo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PATH-27. MOLECULAR, IMAGING, AND SURVIVAL MANIFESTATIONS IN MOLECULAR GLIOBLASTOMAS: INSIGHTS FROM A MULTI-NATIONAL STUDY</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2024-11-11</date><risdate>2024</risdate><volume>26</volume><issue>Supplement_8</issue><spage>viii184</spage><epage>viii184</epage><pages>viii184-viii184</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>Abstract Apart from the traditional definition of IDH-wildtype GBM based on histological characteristics, IDH-wildtype diffuse gliomas previously assigned to histological grade 2 or 3 are now defined as IDH-wildtype GBM in the presence of qualifying molecular markers (TERTp mutation, EGFR amplification, or chromosome +7/-10) (“molecular GBM”) in the 2021 WHO classification. However, the clinical significance of molecular GBM is unrevealed. This collaboration aims to comprehensively evaluate the clinical, molecular, imaging characteristics, and prognosis of molecular GBMs in a multi-national dataset and stratify survival. Retrospective chart and imaging review was performed in 258 molecular GBM patients from eight centers across three continents. Clinical, molecular, imaging, and survival characteristics were analyzed. The median age of molecular GBM patients was 58 years (range: 23-83) with 139 males, with TERTp mutation (83 of 214 [38.8%]), EGFR amplification (160 of 204 [78.4%]), and chromosome +7/-10 (82 of 143 patients [57.3%]). The majority of tumors were located at the frontal and temporal lobes (48.4%) and exhibited non-contrast-enhancing (CE) tumors (73.7%). Gliomatosis cerebri pattern was shown with 27 patients (12.4%). The median OS was 28.1 months (95% confidence interval 22.1-34.1). There was significantly shorter survival in patients with high Ki-67 index (&gt; 20) compared to those with low Ki-67 index (median OS 19.3 vs. 31.5 months, log-rank test P = 0.002), while no survival differences were found according to histological grade or molecular diagnostics. Survival was significantly shorter in patients with infiltrative imaging appearance compared to those without (median OS 24.7 vs 41.0 months, log-rank test P = 0.014). In conclusion, survival within molecular GBM patients may be heterogeneous and associated with Ki-67 index and infiltrative imaging appearance.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/neuonc/noae165.0726</doi></addata></record>
fulltext fulltext
identifier ISSN: 1522-8517
ispartof Neuro-oncology (Charlottesville, Va.), 2024-11, Vol.26 (Supplement_8), p.viii184-viii184
issn 1522-8517
1523-5866
language eng
recordid cdi_crossref_primary_10_1093_neuonc_noae165_0726
source Oxford Journals Online
title PATH-27. MOLECULAR, IMAGING, AND SURVIVAL MANIFESTATIONS IN MOLECULAR GLIOBLASTOMAS: INSIGHTS FROM A MULTI-NATIONAL STUDY
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T15%3A10%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PATH-27.%20MOLECULAR,%20IMAGING,%20AND%20SURVIVAL%20MANIFESTATIONS%20IN%20MOLECULAR%20GLIOBLASTOMAS:%20INSIGHTS%20FROM%20A%20MULTI-NATIONAL%20STUDY&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Park,%20Yae%20Won&rft.date=2024-11-11&rft.volume=26&rft.issue=Supplement_8&rft.spage=viii184&rft.epage=viii184&rft.pages=viii184-viii184&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/noae165.0726&rft_dat=%3Coup_cross%3E10.1093/neuonc/noae165.0726%3C/oup_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c836-7b1e7b90dd758b9dbdcc374c9cfbe22b749f5118acb2440f0cdcb6283c5a3dde3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/neuonc/noae165.0726&rfr_iscdi=true